|
|
||||||||
|
First published online March 7, 2002; 10.1104/pp.010794 Plant Physiol, April 2002, Vol. 128, pp. 1346-1358 Transgenic Expression in Arabidopsis of a Polyprotein Construct Leading to Production of Two Different Antimicrobial Proteins1Centre of Microbial and Plant Genetics, Katholieke Universiteit Leuven, Kasteelpark Arenberg 20, B-3001 Heverlee, Belgium (I.E.J.A.F., M.F.C.D.B., G.D., I.J.W.M.G., P.F.J.W., B.P.A.C., W.F.B.); Flanders Interuniversity Institute of Biotechnology, Rijvisschestraat 120, B-9052 Gent, Belgium (M.F.C.D.B., I.J.W.M.G., P.F.J.W., B.P.A.C.); Afdeling Vergelijkende Fysiologie en Morfologie Dieren, Katholieke Universiteit Leuven, Naamsestraat 59, B-3000 Leuven, Belgium (P.D.V.); Departement Microbiologie en Immunologie, Katholieke Universiteit Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium (P.P.); and Institute for Animal Science and Health (ID-DLO), P.O. Box 65, Lelystad 8200 AB, The Netherlands (W.M.M.S.)
We developed a method for expression in Arabidopsis of a transgene encoding a cleavable chimeric polyprotein. The polyprotein precursor consists of a leader peptide and two different antimicrobial proteins (AMPs), DmAMP1 originating from Dahlia merckii seeds and RsAFP2 originating from Raphanus sativus seeds, which are linked by an intervening sequence ("linker peptide") originating from a natural polyprotein occurring in seed of Impatiens balsamina. The chimeric polyprotein was found to be cleaved in transgenic Arabidopsis plants and the individual AMPs were secreted into the extracellular space. Both AMPs were found to exert antifungal activity in vitro. It is surprising that the amount of AMPs produced in plants transformed with some of the polyprotein transgene constructs was significantly higher compared with the amount in plants transformed with a transgene encoding a single AMP, indicating that the polyprotein expression strategy may be a way to boost expression levels of small proteins.
Genetic modification of plants often requires co-expression of two or more transgenes in addition to a selectable marker gene. For instance, to achieve resistance against a broader range of pathogens in plants, co-expression of transgenes encoding antimicrobial proteins (AMPs) with different biochemical targets is an attractive approach. Other examples include the production of a particular metabolite in plants by co-expressing multiple transgenes that are involved in the biosynthetic pathway of that metabolite. There are different ways to obtain transgenic plants expressing
multiple transgenes. One frequently chosen option is to introduce each
transgene individually via separate transformation events and to cross
the different single transgene-expressing lines (Zhu et al., 1994 A second possibility is to introduce the different transgenes via sequential single-gene transformation steps. The drawback of this method is that a different selectable marker has to be used for every transformation step, which is complicated by the fact that there is only a limited choice of selectable markers. A third possible way is the introduction of the different transgenes as
linked expression cassettes, each with a promoter and terminator,
within a single transformation vector (Slater et al., 1999 A fourth option would be to produce multiple proteins from one
transcription unit by separating the distinct coding regions by
so-called internal ribosomal entry sites, which allow ribosomes to
reiterate translation at internal positions within an mRNA species.
Although internal ribosomal entry sites are well documented in animal
systems (Kaminski et al., 1994 A fifth strategy is based on the production of multiple proteins by
proteolytic cleavage of a polyprotein precursor encoded by a single
transcription unit. Potyviruses, for example, translate their genomic
RNA into a single polyprotein precursor that encompasses domains with
proteolytic activity able to cleave the polyprotein precursor in cis
and to release the individual proteins (Carrington and Dougherty,
1988 We have reported previously on a unique natural polyprotein, IbAMP,
occurring in seeds of the plant Impatiens balsamina (Tailor et al., 1997
Characterization of Transgenic Plants Expressing Polyprotein Constructs with IbAMP-Based Linker Peptides To explore the possibility of exploiting the IbAMP polyprotein
system for co-expression of multiple AMPs, a plant transformation vector (pFAJ3105) was constructed as depicted in Figure
1. In the predicted expression product of
this construct, the fifth propeptide (16 amino acids) of the IbAMP
polyprotein is flanked at either side by the mature protein domain of
the AMPs DmAMP1 and RsAFP2 (50 and 51 amino acids, respectively).
Moreover, the expression product has a leader peptide (28 amino acids)
at its amino-terminus derived from the DmAMP1 precursor. RsAFP2 and
DmAMP1 belong to the family of the plant defensins (Broekaert et al., 1995
Different transgenic T1 generation lines transformed with constructs pFAJ3105 and pFAJ3109, respectively, were analyzed for expression of the transgene both at the mRNA and protein level. Analysis by northern blotting, using the coding region of DmAMP1 as a probe, indicated the presence of transcripts in leaves of lines transformed with either pFAJ3105 or pFAJ3109, but not in untransformed lines (Fig. 2). A clear difference in size of the DmAMP1-specific mRNA in plants transformed with the double protein construct as compared with plants transformed with the single-protein construct could be observed. This size difference is because of the fact that the double protein construct is transcribed as an mRNA coding for the leader peptide, DmAMP1, the linker peptide, and RsAFP2, whereas the single-protein construct is transcribed as an mRNA only coding for the leader peptide and DmAMP1. Quantification of band intensity in nine lines transformed with pFAJ3105 and eight lines transformed with pFAJ3109 indicated that the amounts of transcripts did not differ significantly between both types of transgenic plants (data not shown).
The amount of DmAMP1 and RsAFP2 in leaves from a series of T1 Arabidopsis plants transformed with pFAJ3105 was determined using ELISA assays (Table I). Most of the lines transformed with the polyprotein construct expressed both DmAMP1-cross-reactive proteins (CRPs) and RsAFP2-CRPs. In general, there was a good correlation between DmAMP1-CRP and RsAFP2-CRP levels. However, RsAFP2-CRP levels were generally 2- to 5-fold lower than the DmAMP1-CRP levels. The ELISA assays for measuring the RsAFP2-CRP levels in the extracts were, however, less reliable than those for the DmAMP1-CRPs. In the RsAFP2 ELISA assays, dilutions of extracts of transgenic plants yielded dose-response curves that deviated from those obtained for dilutions of standard solutions containing native RsAFP2, indicating that the majority of the RsAFP2-CRPs in the extracts was not immunologically identical to the native RsAFP2 itself.
The average DmAMP1-CRP expression level of 14 lines transformed with pFAJ3105 was 0.62% of total soluble protein content versus only 0.09% for eight lines transformed with pFAJ3109, indicating that the polyprotein construct resulted in a dramatic increase in expression level as compared with the single-protein construct (Fig. 3). Statistical analysis demonstrated that this difference in expression level is significantly different (P < 0.05).
To test whether enhanced expression observed for the polyprotein construct pFAJ3105 is restricted to the particular configuration of the expression unit, four other constructs (pFAJ3339, pFAJ3340, pFAJ3433, and pFAJ3375) were made (Fig. 1). The promoter used in these constructs was the chimeric promoter [uOcs]pMas, consisting of the A. tumefaciens octopine synthase enhancer linked to the A. tumefaciens mannopine synthase promoter instead of the CaMV35S promoter used in construct pFAJ3105. The terminator was the mannopine synthase terminator instead of the nopaline synthase terminator used in construct pFAJ3105. Constructs pFAJ3339 and pFAJ3340 are both polyprotein-encoding constructs, with the polyprotein encoded by pFAJ3339 being exactly the same as the polyprotein encoded by pFAJ3105 and the one encoded by pFAJ3340 having a reversed order of the DmAMP1 and RsAFP2 coding regions relative to that of pFAJ3105 and pFAJ3339. Constructs pFAJ3433 and pFAJ3375 are both single-protein constructs, with pFAJ3433 encoding mature DmAMP1 preceded by the DmAMP1 leader peptide at its amino terminus and pFAJ3375 encoding mature RsAFP2 with the DmAMP1 leader peptide. Comparison of the expression levels in the different transgenic plant populations (Table II) revealed that DmAMP1-CRP and RsAFP2-CRP levels in the polyprotein construct pFAJ3339 plants were on average 9- and 8-fold higher relative to the levels in the single-protein constructs pFAJ3433 and pFAJ3375 plants, respectively (Fig. 4). The RsAFP2-CRP levels in plants carrying the polyprotein construct pFAJ3340 were on average 3-fold higher than those in pFAJ3375 plants expressing only RsAFP2. There was, however, no significant difference in DmAMP1-CRP levels between polyprotein construct pFAJ3340 plants and pFAJ3433 plants expressing only DmAMP1.
Analysis of the Subcellular Location of Co-Expressed Plant Defensins To determine whether the co-expressed plant defensins are either secreted extracellularly or deposited intracellularly, extracellular fluid and intracellular extract fractions were prepared from leaves of Arabidopsis plants transformed with the polyprotein construct (pFAJ3105). The cytosolic enzyme Glc-6-phosphate dehydrogenase was used as a marker to detect contamination of the extracellular fluid fraction with intracellular components. Glc-6-phosphate dehydrogenase was partitioned in a ratio of 83:17 between the intracellular extract fractions and extracellular fluid fractions. In contrast, 94% of DmAMP1-CRP content and 92% of RsAFP2-CRP content in the transgenic plants tested were found in the extracellular fluid fractions. These results indicate that both plant defensins released from the polyprotein precursors are deposited primarily in the apoplast. Purification of Proteins Processed from Polyprotein Construct pFAJ3105 DmAMP1-CRPs and RsAFP2-CRPs were purified by reverse-phase (RP) HPLC from extracellular fluid prepared from leaves of transgenic Arabidopsis plants transformed with construct pFAJ3105 (homozygous T2 plants derived from line 12, see Table I). Extracellular fluid was obtained as described in "Materials and Methods," using a buffer which contained a mixture of protease inhibitors (phenylmethylsulfonylfluoride, N-ethylmaleimide, ethylenediaminotetra-aceticacid, and pepstatinA). The collected extracellular fluid was analyzed by RP-HPLC on a C8-silica column and the collected fractions were tested for the presence of DmAMP1-CRPs and RsAFP2-CRPs using ELISA assays. The result of this analysis is shown in Figure 5. DmAMP1-CRPs eluted in two fractions, the latter of which eluted at a position very close to that of native DmAMP1. RsAFP2-CRPs were found in a single peak that eluted at a position very close to that of native RsAFP2 and that was well separated from the DmAMP1-CRP peaks. None of the tested fractions reacted with both the anti-DmAMP1 and anti-RsAFP2 antibodies, indicating that an uncleaved immunoreactive fusion protein was absent from the extracellular fluid. Based on comparison of integrated peak areas of the DmAMP1-CRPs and RsAFP2-CRPs with those of a series of standards consisting of native DmAMP1 and RsAFP2, respectively, it was estimated that the extract for the line transformed with the polyprotein construct pFAJ3105 contained about equal amounts of DmAMP1 and RsAFP2. This indicates that cleavage of the polyprotein precursor in this line results in about equimolar amounts of DmAMP1-CRPs and RsAFP2-CRPs. Similar chromatograms were obtained upon analysis of the extracellular fluid prepared from other transgenic lines (data not shown), indicating that the chromatographic pattern of DmAMP1-CRPs and RsAFP2-CRPs is independent from the transgenic line tested.
To test whether the purification procedure based on the extracellular fluid preparation reflects the true composition in DmAMP1-CRPs and RsAFP2-CRPs of the transgenic Arabidopsis leaves, an alternative purification procedure was developed starting from a crude leaf extract. The extract was fractionated by ion-exchange chromatography (IEC) and subsequently by RP-HPLC. After separation, fractions were collected and assessed for the presence of DmAMP1-CRPs and RsAFP2-CRPs using ELISA assays. IEC was performed by passing the extract over a cation exchange column at pH 6. When the column was eluted with a linear gradient of 0 to 0.5 M NaCl in 50 mM MES at pH 6, DmAMP1-CRPs were detected in fractions eluting between 0.17 and 0.33 M NaCl, whereas RsAFP2-CRPs were detected in fractions eluting between 0.24 and 0.49 M NaCl (data not shown). Fractions containing either DmAMP1-CRPs or RsAFP2-CRPs were pooled into two fractions (0.17-0.24 M NaCl and 0.33-0.49 M NaCl, respectively), which were each subjected to RP-HPLC on a C8-silica column eluted with a linear gradient of acetonitrile. DmAMP1-CRPs eluted in two peaks, the latter of which eluted at a position very close to that of native DmAMP1. RsAFP2-CRPs were found in a single peak that was well separated from the DmAMP1-CRP peaks and eluted at a position very close to that of native RsAFP2 (data not shown). Molecular Analyses of the Purified Protein Fractions The different DmAMP1-CRPs and RsAFP2-CRPs purified from the extracellular fluid were subjected to amino-terminal amino acid sequence analysis as well as to mass spectrometry. The carboxy-terminal amino acid was determined based on the best approximation of the predicted theoretical mass to the experimentally determined mass (Table III). The DmAMP1-CRPs, p3105EF1 and p3105EF2 (nomenclature as in Fig. 5), had masses that were consistent with the presence of a single additional Ser residue at their carboxy-terminal end as compared with native DmAMP1. However, whereas the mass of p3105EF2 corresponded exactly (within experimental error) to that calculated for a DmAMP1 derivative with an additional Ser (hereafter called DmAMP1+S) at its carboxy-terminal end, the mass of p3105EF1 was in excess by 4 D relative to the calculated mass for DmAMP1+S. Hence, this protein might be a DmAMP1+S derivative with partially reduced disulfide bridges. This hypothesis was confirmed by reduction of the disulfide bonds in p3105EF1 and p3105EF2 with excess dithiothreitol, followed by separation of the reduced forms by RP-HPLC. The reduced form of p3105EF1 and p3105EF2 eluted at exactly the same position, indicating that p3105EF1 only differs from p3105EF2 in its disulfide bond content (data not shown).
The RsAFP2-CRP fraction p3105EF3 represents an RsAFP2 derivative with the additional pentapeptide sequence DVEPG at its amino terminus, corresponding to the five carboxy-terminal amino acids of the linker peptide. This protein is further referred to as DVEPG+RsAFP2. The different DmAMP1-CRPs and RsAFP2-CRPs purified from total leaf extract from plants transformed with construct pFAJ3105 were analyzed in the same way. The analyses indicated that the same three molecular species were present in the total leaf extract, namely DmAMP1+S, a reduced form of DmAMP1+S and DVEPG+RsAFP2 (data not shown). In addition, DmAMP1-CRPs and RsAFP2-CRPs were also purified from extracellular fluid of plants transformed with construct pFAJ3340, the construct in which the order of DmAMP1 and RsAFP2 in the polyprotein was reversed. In this case, the molecular entities identified were authentic RsAFP2 including a pyro-Glu residue at its amino-terminus, RsAFP2 with an amino-terminal pyro-Glu and an additional carboxy-terminal Ser (RsAFP2+S), and finally DmAMP1 with an additional amino-terminal pentapeptide (DVEPG+DmAMP1; data not shown). In the plants transformed with polyprotein construct pFAJ3340, no reduced or partially reduced forms of either DmAMP1-CRPs or RsAFP2-CRPs could be detected (data not shown). In Vitro Antifungal Activity of the Purified Proteins The antifungal activity of the purified fractions from the extracellular fluid of plants transformed with construct pFAJ3105, containing the major processed products DmAMP1+S and DVEPG+RsAFP2, respectively, were assayed using Fusarium culmorum as a test fungus (Table IV). The specific antimicrobial activity, expressed as protein concentration required for 50% growth inhibition of the test organism, of purified DmAMP1+S appeared to be identical to that of native DmAMP1. The specific antimicrobial activity of purified DVEPG+RsAFP2, however, was about 2-fold lower relative to that of native RsAFP2. The slight drop in antimicrobial activity of DVEPG+RsAFP2 is most likely because of the presence of the five additional amino-terminal amino acids. Nevertheless, our data prove that processing of the polyprotein precursors in transgenic plants can result in the release of bioactive proteins.
In this paper, we have described the expression and processing in transgenic Arabidopsis plants of a chimeric polyprotein consisting of a leader peptide domain and two mature protein domains, corresponding respectively to the AMPs DmAMP1 and RsAFP2, separated from each other by a 16-amino acid-linker peptide corresponding to the fifth propeptide of the IbAMP precursor. Our data indicate that the polyprotein precursor is cleaved to release bioactive derivatives of the mature AMPs DmAMP1 and RsAFP2. The processing of the polyprotein precursor encoded by construct pFAJ3105 appears to occur in at least two steps. At first, the polyprotein precursor is cleaved upon translation to release the leader peptide as occurs during the maturation of native DmAMP1. The remaining part of the polyprotein precursor is then cleaved at one or more unknown positions in the linker peptide, giving rise to a DmAMP1 derivative with an additional carboxy-terminal Ser and an RsAFP2 derivative with an additional pentapeptide (DVEPG) at its amino terminus (Fig. 6). The polyprotein precursor encoded by construct pFAJ3340, in which the order of the mature DmAMP1 and RsAFP2 domains is reversed relative to that of pFAJ3105, is cleaved at almost the same positions as for the polyprotein precursor encoded by pFAJ3105. One small difference is that cleavage of the first protein (RsAFP2 in the case of pFAJ3340) occurs both after the mature RsAFP2 domain and after the immediately adjacent Ser (Fig. 6). This indicates that cleavage within the IbAMP linker peptide is largely independent of the sequence context at both the amino- and carboxy-terminal ends.
The protease (or group of proteases) responsible for these cleavages is
not known. Endoproteinases or a combination of endo- and exoproteinases
could be responsible for these cleavages. In the latter case, it
is possible that a first cleavage occurs by the action of an
endoproteinase, whereas exoproteinases would be responsible for the
subsequent trimming of the cleavage products. It is possible that the
carboxy terminus of the linker peptide is cleaved by an endoproteinase
between two acidic amino acids, Glu and Asp. A comparison of the
amino acid sequence of the five propeptides of the natural polyprotein
precursor isolated from I. balsamina (Tailor et al., 1997 Deposition of AMPs in the apoplast of transgenic plants is preferred
for the purpose of engineering disease-resistant plants because most
pathogenic microorganisms occur at least during the early stages of
infection in the extracellular space. The polyprotein expression system
based on the IbAMP propeptide is the first of its kind to succeed in
extracellular deposition of the processed mature proteins. Previous
reports on polyprotein expression systems (Marcos and Beachy, 1994 In plants transformed with the polyprotein construct pFAJ3105, a minor
fraction of the DmAMP1-processed product occurred in a form in which
two of the four disulfide bridges are not formed, whereas this was not
observed for the RsAFP2-processing product. The reason for this
incorrect maturation of DmAMP1 is currently unclear. One possible
explanation is that cleavage of the [DmAMP1]-[IbAMP linker]-[RsAFP2] precursor occurs in the Golgi apparatus, whereas folding and disulfide formation occurs in the endoplasmic reticulum. The nature of the precursor may hamper proper folding of the
amino-terminal DmAMP1 domain in a fraction of the precursor molecules,
leading to incomplete cystine formation that is known to be assisted by disulfide isomerases residing in the endoplasmic reticulum (Vitale and
Denecke, 1999 A striking observation from our experiments is that DmAMP1-CRP and
RsAFP2-CRP levels in the lines transformed with a polyprotein construct
are on average severalfold higher as compared with those in the lines
transformed with the corresponding single-protein construct,
respectively. The only exception was the level of DmAMP1-CRPs in plants
transformed with the polyprotein construct pFAJ3340, which was not
significantly different from the level of DmAMP1-CRPs in plants
transformed with the single-protein construct pFAJ3433. Expression
levels as high as 1.35% of total protein content, as seen in some
lines transformed with pFAJ3105, have so far never been reported in the
literature for a peptide expressed in leaves of transgenic plants. The
fusion of a small peptide to another protein as a way to enhance its
expression level has been suggested by another recent observation.
Okamoto et al. (1998) In our polyprotein precursor constructs in which DmAMP1 was the first protein and RsAFP2 the second (pFAJ3105 and pFAJ3339), production of DmAMP1-CRPs was consistently higher than that of RsAFP2-CRPs, as measured by ELISA assays. However, when analyzed by chromatography, the fraction of DmAMP1-CRPs and RsAFP2-CRPs appeared to be equal. We believe that the apparently lower RsAFP2-CRP content versus the DmAMP1-CRP content in those plants is because of suboptimal recognition of DVEPG+RsAFP2 by the antibodies raised against RsAFP2. ELISA assays performed with extracts containing DVEPG+RsAFP2 always showed deviating dose-response curves. Moreover, studies of the interactions of anti-RsAFP2 antibodies with a series of synthetic 15-mer peptides, representing an overlapping series of the entire RsAFP2 sequence, revealed that these antibodies react most strongly with peptides representing the amino-terminal end (A.Van Amerongen, personal communication). Hence, the DVEPG sequence in DVEPG+RsAFP2 may partially mask the most immunoresponsive epitope. In plants transformed with construct pFAJ3340, in which RsAFP2-CRPs are present with their authentic amino-terminal end, RsAFP2-CRPs and DmAMP1-CRPs were expressed at approximately equal levels. In current experiments, we are adapting the linker peptide used in the polyprotein constructs in an attempt to ensure a more correct cleavage of the polyprotein construct with the aim to release the individual AMPs with a minimal number of additional amino acids at their amino or carboxy terminus.
Construction of Plant Transformation Vectors The polyprotein encoding sequences of plasmid
pFAJ3105 (shown in Fig. 1) was constructed following the two-step
recombinant PCR protocol of Pont-Kingdon (1994) For the construction of plasmid pFAJ3109, the NcoI-SacI fragment of plasmid pDMAMPD containing the DmAMP1 cDNA (gift from Dr. Ian Evans, Zeneca Agrochemicals) was first cloned into the corresponding sites of the expression vector pMJB1, and the HindIII-EcoRI fragment of this plasmid was subsequently cloned in the corresponding sites of plant transformation vector pGPTVbar (see above). For the construction of plasmid pFAJ3339, the
NcoI- SacI fragment of
plasmid pFAJ3099 was cloned into pMODUL3460, which is a derivative of
the vector pMODUL3459 (Goderis et al., 2002 For the construction of plasmid pFAJ3340, several PCR reactions were performed. At first, an inverse PCR reaction with primers OWB520 (sense, 5' GAGGACGTGGAACCT GGTCAGAAGTTGTGCC) and OWB521 (antisense, 5' TGGGGTAGCCACCTCGTCGGCC GCGTTGGAAC) was performed on plasmid pFAJ3099 to yield plasmid pFAJ3312 with silent mutations in the linker peptide to incorporate additional restriction sites in the coding region of the linker peptide (EagI site at the 5' end of the linker peptide-coding region and SexAI site at the 3' end of the linker peptide-coding region). A second PCR reaction was performed on plasmid pFAJ3099 with primers OWB452 (sense, 5' TTACACCATGGTGAA TCGGTCGGTTGCGTTCTCCGCGTTCGTTCTGATCCTTTTCGTGCTCGCCATCTCAGATATCGCATCCGTTAGTGGACAGAAGTTGTGCCAAAGG C) and OWB519 (antisense, 5' CGGCCGCGTTGGAACACGGGAAGTAGCAGATACAC) to attach the coding region of the leader peptide of DmAMP1 at the 5' end of the RsAFP2 coding region and the 5' part of the coding region of the linker peptide (together with the EagI restriction site) at the 3' end of RsAFP2 coding region. The resulting PCR product was cloned into pGEM-T (Promega, Madison, WI) to yield plasmid pFAJ3313. A third PCR reaction was performed on plasmid pDMAMPD with primers OWB517 (sense, 5' AACCTGGTGAACTA TGCGAGAAAGCTAGC) and OWB518 (antisense, 5' GAGCTCTATTAGCAGTTGAAGT AACAGAAACAC) to attach the 3' part of the linker peptide coding reigon at the 5' end of the DmAMP1 coding region. The resulting PCR product was cloned into pGEM-T to yield pFAJ3314. The NcoI-EagI fragment of pFAJ3313 and the SexAI-SacI fragment of plasmid pFAJ3314 were cloned into the corresponding restriction sites of plasmid pFAJ3312 to yield pFAJ3324. The NcoI-SacI fragment of pFAJ3324 was cloned into the corresponding restriction sites of plasmid pMODUL3460 to yield plasmid pFAJ3328. The I-SceI fragment of plasmid pFAJ3328 was cloned into the corresponding restriction site of plasmid pFAJ3337 to yield plasmid pFAJ3340. For the construction of plasmid pFAJ3433, the NcoI-SacI fragment of plasmid pDMAMPD containing the DmAMP1 cDNA was first cloned into the corresponding restriction sites of plasmid pMODUL3460 to yield plasmid pFAJ3432. The I-SceI fragment of plasmid pFAJ3432 was cloned into the corresponding restriction site of plasmid pFAJ3337 to yield plasmid pFAJ3433. For the construction of plasmid pFAJ3375, a PCR reaction with primers OWB452 (sense, 5' TTACACCATGGTGAATCGGTCGGTTGCGTTCTCCGCGTTCGTTCTGATC CTTTTCGTGCTCGCCATCTCAGATATCGCATCCGTTAGTGGACAGAAGTTGTGCCAAAGGC) and OWB172 (antisense, 5' TTAGAGCTCCTATTAACAAGGAAAGTAGC) was performed on plasmid pFAJ3099. The resulting PCR product was digested with NcoI and SacI and cloned into the plasmid pMODUL3460 to yield plasmid pFAJ3364. The I-SceI fragment of pFAJ3364 was cloned into the corresponding restriction site of plasmid pFAJ3337 to yield plasmid pFAJ3375. Plant Transformation Arabidopsis ecotype Columbia-O was transformed using recombinant
A. tumefaciens by the vacuum infiltration method of
Bechthold et al. (1993) ELISA Assay and Protein Assay Antisera were raised in rabbits injected with either DmAMP1
(purified as in Osborn et al., 1995 Total protein content was determined according to Bradford (1976) Statistical analysis of expression levels in plant extracts (expressed as micrograms DmAMP1 or RsAFP2 equivalents per milligram of total protein) was performed. Because of the non-normal distribution of the datasets (as shown by QQplots), a natural logarithm transformation of the datasets was performed. These logarithm-transformed datasets were analyzed by using the Tukey's studentized range test with a significance level of 95%. Northern-Blot Assay Extraction of RNA from Arabidopsis leaves and northern-blot
analysis via chemiluminiscent detection were performed as described by
Eggermont et al. (1996) Preparation of Extracellular Fluid, Intracellular Extract, and Crude Leaf Extract Extracellular fluid was collected from Arabidopsis leaves by
immersing the leaves in a beaker containing extraction buffer. The
extraction buffer used to analyze secretion of the AMPs consisted of
100 mM KCl, 9.6 mM
NaH2PO4.2H2O, 15.2 mM
Na2HPO4.2H2O, and 1.5 M
NaCl (pH 7). The extraction buffer used to conduct cleavage analyses
consisted of 50 mM MES, 1 mM
phenylmethylsulfonylfluoride, 1 mM
N-ethylmaleimide, 5 mM EDTA, and 0.02 mM pepstatinA (pH 6). The beaker was placed in a vacuum
chamber and subjected to six consecutive rounds of vacuum for 2 min
followed by abrupt release of vacuum. The infiltrated leaves were
gently placed in a centrifuge tube on a grid separated from the tube
bottom. The extracellular fluid was collected from the bottom of the
tube after centrifugation of the tubes for 15 min at 1,800g.
The leaves were extracted in a Phastprep (BIO101/Savant,
Toronto) reciprocal shaker (Eggermont et al., 1996 To prepare a crude leaf extract, Arabidopsis leaves were homogenized under liquid nitrogen and extracted with 50 mM MES (pH 6) containing a mixture of protease inhibitors (1 mM phenylmethylsulfonylfluoride, 1 mM N-ethylmale-imide, 5 mM EDTA, and 0.02 mM pepstatinA). The homogenate was cleared by centrifugation (10 min at 10,000g) and the supernatant is referred to as the crude leaf extract. Glc-6-Phosphate Deydrogenase Test Glc-6-phosphate dehydrogenase activity was measured according to
a modified protocol of Simcox et al. (1977) Separation of Proteins Processed from Polyprotein Precursors Encoded by Constructs pFAJ3105 and pFAJ3340 Extracellular Fluid Extracellular fluid (collected as described above) was injected on an RP-HPLC column consisting of C8 silica (0.46 × 25 cm, Varian, Palo Alto, CA) equilibrated with 15% (w/v) acetonitrile in 0.1% (v/v) TFA. The column was eluted at 1 mL min 1 in a linear gradient in 35 min from 15% to 50%
(w/v) acetonitrile in 0.1% (v/v) TFA. The eluate was monitored
for A280 and individual peak fractions were
collected and analyzed for the presence of DmAMP1-CRPs and RsAFP2-CRPs
by ELISA assays. Fractions that contained DmAMP1-CRPs and RsAFP2-CRPs
were evaporated and used for amino-terminal sequence analysis, mass
spectrometry, and in vitro antifungal activity assay.
Crude Leaf Extract Crude leaf extract from plants transformed with construct pFAJ3105 was fractionated by IEC. IEC was performed by passing the extract over a cation-exchange column (Mono S, 5 × 50 mm, Pharmacia Biotech, Piscataway, NJ) equilibrated with 50 mM MES at pH 6. The column was eluted with a linear gradient of 0 to 0.5 M NaCl in 50 mM MES at pH 6 at a flow rate of 1 mL min 1 and 1-mL fractions were
collected. Fractions were assessed for the presence of DmAMP1-CRPs and
RsAFP2-CRPs via ELISA assay (as described above). Fractions containing
either DmAMP1-CRPs or RsAFP2-CRPs were further fractionated by RP-HPLC
as described above.
Assessment of Protein Levels The concentration of purified DmAMP1 and RsAFP2 in solution was determined by weighing lyophilized proteins before dissolving. Known amounts of either purified DmAMP1 or RsAFP2 (5, 10, and 20 µg) were added to partially purified extracellular fluid from wild-type plants and the mixtures were subjected to HPLC as described above. The protein amounts of the protein standards were related to the area of the peaks corresponding to DmAMP1-CRPs or RsAFP2-CRPs as determined with an HP3396 series II integrator. This correlation of protein amount to peak area was used to determine protein amounts in HPLC chromatogram peaks, integrated using the same settings as for the protein standards, corresponding to DmAMP1-CRPs or RsAFP2-CRPs in samples consisting of partially purified extracellular fluid from transgenic plants, assuming that the peaks consisted purely of DmAMP1 or RsAFP2, respectively.Reduction of Proteins Reduction of proteins was performed by adding Tris-HCl (pH 8.4) and dithiotreitol to final concentrations of 100 mM, followed by incubation at 45°C for 1 h. Reagents were removed by RP-HPLC on a C8 silica column (0.46 × 25 cm, Rainin). Antifungal Activity Assay Antifungal activity was measured by microspectrophotometry
(Broekaert et al., 1990
We thank Katleen Butaye for her guidance on the statistical analyses.
Received August 3, 2001; returned for revision October 31, 2001; accepted December 21, 2001. 1 This research was partially supported by the "Instituut voor de aanmoediging van Innovatie door Wetenschap en Technologie in Vlaanderen" (grant no. SB971156), by the European Union (grant no. AIR2-CT94-1356), and by Zeneca Agrochemicals (UK). I.E.J.A.F. is the recipient of a predoctoral fellowship of the "Instituut voor de aanmoediging van Innovatie door Wetenschap en Technologie in Vlaanderen."
2 Present address: Western Australia State Agriculture Biotechnology Centre, Division of Science and Engineering, Murdoch University, Perth, WA 6750, Australia.
3 Present address: CropDesign N.V., Technologiepark 3, B-9502 Gent, Belgium.
* Corresponding author; e-mail Bruno.Cammue{at}agr.kuleuven.ac.be; fax 32-16-32-19-66.
Article, publication date, and citation information can be found at www.plantphysiol.org/cgi/doi/10.1104/pp.010794.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||